EUVIMEDEUVIMED entdecken
Crossref

A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity

Jiarong Mao, Zhetong Jin, Xue Rui, Lu Li, Chengchen Hou, Xuejiao Leng, Xiaolin Bi, Zhipeng Chen, Yugen Chen, Jingjing Wang iD

Advanced Healthcare Materials · 2023

DOI: 10.1002/adhm.202301099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Jiarong Mao und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, P. R. China. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, there is still an intense demand for a simple and scalable delivery platform for peptide‐based cancer vaccines. Herein, a cyclodextrin‐based polymer nanovaccine platform (CDNP) is designed for the codelivery of peptides with two immune adjuvants [the Toll‐like receptor (TLR)7/8 agonist R848 and the TLR9 agonist CpG] that is broadly applicable to epitope peptides with diverse sequences. Specifically, the cyclodextrin‐based polymers are covalently linked to epitope peptides via a bioreactive bond‐containing cross‐linker (PNC‐DTDE‐PNC) and then physically load with R848 and CpG to obtain CDNP. The CDNP efficiently accumulats in the lymph nodes (LNs), greatly facilitating antigen capture and cross‐presentation by antigen‐presenting cells. The immunogenicity of the epitope peptides is significantly enhanced by the codelivery and synergy of the adjuvants, and the CDNP shows the ability to inhibit tumor progression in diverse tumor‐bearing mouse models. It is concluded that CDNP holds promise as an optimized peptide‐based cancer vaccine platform.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsNanoparticlesAnimalsMiceEpitopesAntigen-Presenting CellsAdjuvants, ImmunologicPeptidesMice, Inbred C57BLImmunotherapy

Stichwörter der Autor:innen

cancer immunotherapyepitope peptidesnanovaccineβ-cyclodextrin

Substanzen

EpitopesCancer VaccinesAdjuvants, ImmunologicPeptides

Autor:innen und Institutionen

  • The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, P. R. China.
  • School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210000, P. R. China.

ORCID-Profile: Jingjing Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Mao, J., Jin, Z., Rui, X., Li, L., Hou, C., Leng, X., Bi, X., Chen, Z., Chen, Y., & Wang, J. (2023). A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202301099

Vancouver

Mao J, Jin Z, Rui X, Li L, Hou C, Leng X, et al. A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202301099

BibTeX
@article{Mao2023,
  author = {Mao, Jiarong and Jin, Zhetong and Rui, Xue and Li, Lu and Hou, Chengchen and Leng, Xuejiao and Bi, Xiaolin and Chen, Zhipeng and Chen, Yugen and Wang, Jingjing},
  title = {A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity},
  journal = {Advanced Healthcare Materials},
  year = {2023},
  doi = {10.1002/adhm.202301099}
}
Kostenlos starten →